Pharmacokinetic considerations on monoclonal antibodies.
Dedrick
R L
RL
Biomedical Engineering and Instrumentation Branch, National Institutes of Health, Bethesda, MD 20892.
Flessner
M F
MF
D000008:Abdominal Neoplasms / Q000378:metabolism / Q000628:therapy; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000032:analysis*; D001202:Ascitic Fluid / Q000378:metabolism; D001692:Biological Transport; D002199:Capillary Permeability; D004333:Drug Administration Routes; D006801:Humans; D000922:Immunotoxins / Q000378:metabolism / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy; D009374:Neoplasms, Experimental / Q000378:metabolism / Q000628:therapy; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D000922:Immunotoxins